ArticleBMC veterinary research2025
In vitro expression of the goose astrovirus Cap protein delivered with a duck enteritis virus vector.
Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Construction and characterization of recombinant duck enteritis virus expressing duck hepatitis A virus 3 immunogenic genes.Poultry science · 2026Article
- Distinct intracellular and extracellular maturation of goose astrovirus 2 capsid protein and the potential of virus-like particles as a novel subunit vaccine.Frontiers in veterinary science · 2026Article
- Rapid extraction-free RT-RAA assay for on-site detection of goose astrovirus type 1 in goslings.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundGoose astrovirus (GAstV) is an emerging pathogen that is widely distributed throughout China and can cause visceral gout, resulting in serious economic losses for the goose industry. Open reading frame 2 (ORF2) of this virus encodes the precursor capsid protein, which is essential for the assembly and antigenicity of these virions. To construct a bi-valent vaccine for controlling GAstV and duck enteritis virus (DEV) infection, an infectious bacterial artificial chromosome (BAC) clone of the DEV vaccine strain pDEV-EF1 was used to establish a recombinant DEV vector for GAstV ORF2 gene delivery.
methodsGAstV ORF2 expression frame was inserted into the US7 and US8 intergenic region of DEV genome by Red E/T two-step recombinant technology, then the recombinant virus rDEV-GAstV ORF2 was rescued by transfecting recombinant clone pDEV-GAstV ORF2 into chicken embryonic fibroblasts (CEFs). The expression of ORF2 in CEFs and formation of virus-like particles (VLPs) were analysed by Western blotting, indirect immunofluorescence assay (IFA) and immunogold electron microscopy (IEM), individually. And protein celluar localization was analysed by IFA.
resultsUsing this rDEV-GAstV ORF2 vector to infect CEFs was sufficient to elicit GAstV Cap protein expression, as confirmed by Western blotting and IFA. IEM also revealed the formation of VLPs within cells expressing this Cap protein.
conclusionsDEV is a good viral vector for GAstV ORF2 gene delivery and these results provide a basis for the development of a bivalent vaccine for controlling DEV and GAstV infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.